Sermorelin
GHRH(1–29) analog · pituitary GH secretagogue
A synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH), FDA approved for diagnosing and treating pediatric growth hormone deficiency. Preserves the body's natural pulsatile GH release pattern for optimized GH levels with fewer side effects than direct HGH injection.

Sermorelin is a 29-amino-acid peptide identical to the active fragment of the growth hormone-releasing hormone (GHRH) your hypothalamus already produces. The full GHRH molecule is 44 amino acids, but research established that the first 29 carry all the biological activity. The FDA approved sermorelin (brand name Geref) in 1997 for diagnosing and treating growth hormone deficiency in children. Off-label adult use for GH optimization became widespread in the 2000s as a safer alternative to direct HGH injection, and the peptide became one of the most widely prescribed compounds in anti-aging medicine following patent expiration.
Sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering GH release in a pulsatile pattern that mirrors the body's natural rhythm — primarily during deep sleep and after exercise. This is the key distinction from direct HGH injection. Exogenous HGH bypasses the body's regulatory feedback loops entirely, producing constant elevated GH levels with risk of insulin resistance, joint pain, and fluid retention. Sermorelin works through the pituitary's existing regulatory architecture. After GH release, natural feedback mechanisms (somatostatin, IGF-1) modulate further secretion. The downstream effects include increased IGF-1 production, improved protein synthesis, enhanced lipolysis, better sleep architecture, and improved tissue repair.
Sleep improvement is consistently the first benefit users notice, often within the first week. Body composition changes — reduced fat, preserved lean muscle — are slower but sustained over 3 to 6 months. Exercise recovery improves as GH-driven tissue repair accelerates. The overall effect profile is the same as optimized GH levels, arrived at through a mechanism the body is already designed to use.
Community Experiences
"The first time in years I slept through the night without waking up at 3 AM. Sleep quality improved within the first week. That alone is worth it." — r/Peptides
"The body composition changes are slow — you're not going to look different in a month. But at 12 weeks the difference in how you feel and how you look is real." — r/Peptides
"Compared to injecting actual HGH, sermorelin is just smoother. You're not overriding your body, you're asking it nicely. The side effect profile is completely different." — r/Biohackers

Growth hormone secretagogue research for optimized GH release
Frequently Asked Questions
Is sermorelin FDA approved? Yes. Sermorelin was FDA approved in 1997 for diagnosing and treating growth hormone deficiency in children. Adult use for GH optimization is off-label and widely practiced in anti-aging medicine.
How does sermorelin differ from HGH? Sermorelin stimulates the pituitary to release GH in natural pulses. Direct HGH injection bypasses regulatory feedback, providing constant elevated levels with a higher risk of side effects including insulin resistance and joint pain.
What is the typical research dose? Common protocols use 100 to 300 mcg administered subcutaneously at bedtime, aligned with the body's natural GH release pattern during deep sleep.
How long before results appear? Sleep improvements often appear within the first week. Body composition and recovery benefits typically take 8 to 12 weeks of consistent use.
Stacking Suggestions
- Ipamorelin for a synergistic GH release stack — sermorelin via GHRH receptors, ipamorelin via ghrelin receptors, combined GH output
- CJC-1295 for extended GHRH receptor stimulation with a longer half-life
- BPC-157 for tissue repair support while sermorelin optimizes GH levels
- GHK-Cu for skin health benefits that complement sermorelin's GH-mediated skin improvements
- MOTS-c for metabolic support alongside GH optimization
Verified Literature & Trial Registry · NCBI PubMed & ClinicalTrials.gov
Sermorelin: Indexed Studies & Clinical Trials
Evidence & Scope Notice (R06): The records below are retrieved directly from NCBI PubMed and ClinicalTrials.gov. Preclinical (rodent/in vitro) studies do not establish human safety or efficacy. This index is for educational research literacy only and is never medical advice.
Registered Human Clinical Trials (ClinicalTrials.gov)
Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers
Conditions: Healthy Volunteer Study
Primary Endpoint: Percentage of subjects reporting adverse events (AEs)/serious adverse events (SAEs).
Effects of Growth Hormone Releasing Hormone in HIV
Conditions: HIV, HIV Lipodystrophy
Primary Endpoint: Liver Fat
SMART: Somatotrophics, Memory, and Aging Research Trial
Conditions: Aging, Mild Cognitive Impairment
Primary Endpoint: Change in declarative memory, including total recall scores on three tests of memory and on dual task response time (RT), a test of executive function.
Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly
Conditions: Acromegaly
Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly
Conditions: Elderly
Primary Endpoint: Change in Lean Body Mas
The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure
Conditions: Congestive Heart Failure
Primary Endpoint: PP1- Serum IGF-1 Levels, DXA, Resting Metabolic Rate, Total Body Water, 3-D Echo, Cardiac MRI, Dobutamine Stress Echocardiogram, Ergometry, General Health Assessment, Physical Exam
Selected Peer-Reviewed PubMed Literature
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Walker RF · DOI: 10.2147/ciia.2006.1.4.307
Advances in the detection of growth hormone releasing hormone synthetic analogs
Memdouh S, Gavrilović I, Ng K et al. · DOI: 10.1002/dta.3183
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
Prakash A, Goa KL · DOI: 10.2165/00063030-199912020-00007
A potentially effective drug for patients with recurrent glioma: sermorelin
Chang Y, Huang R, Zhai Y et al. · DOI: 10.21037/atm-20-6561
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
Coutinho LFD, DE Oliveira Neves LF, Camilo RP · DOI: 10.23736/S0022-4707.26.17773-1
Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males
Sinha DK, Balasubramanian A, Tatem AJ et al. · DOI: 10.21037/tau.2019.11.30